We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Cancer Drugs Now Account for 27 Percent of New U.S. Approvals: Tufts
Cancer Drugs Now Account for 27 Percent of New U.S. Approvals: Tufts
Cancer drugs now account for 27 percent of all new drug approvals in the U.S., up from just four percent in the 1980s — in part because of improved trial designs, novel drug formats and new targets — according to a new study from the Tufts Center for the Study of Drug Development (CSDD).